Combination Therapy for Advanced Cancer
Author Information
Author(s): Jones P H, Christodoulos K, Dobbs N, Thavasu P, Balkwill F, Blann A D, Caine G J, Kumar S, Kakkar A J, Gompertz N, Talbot D C, Ganesan T S, Harris A L
Primary Institution: Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford, UK
Hypothesis
Can a combination of captopril, marimastat, and low molecular weight heparin improve treatment outcomes in patients with advanced cancer?
Conclusion
The combination therapy was generally well tolerated and showed some activity in renal carcinoma, but further studies are needed to confirm its efficacy.
Supporting Evidence
- The combination therapy showed a partial response in one patient with renal carcinoma.
- Three patients with renal carcinoma experienced prolonged disease stabilization.
- Serious toxicity was mainly due to major bleeding events.
Takeaway
Doctors tested a mix of three medicines to see if they could help people with serious cancer. They found that it worked a little for some patients, especially those with kidney cancer.
Methodology
A phase 2 clinical trial with patients aged over 18 years who had advanced malignancy and were treated with a combination of captopril, marimastat, and low molecular weight heparin.
Potential Biases
Potential bias due to the lack of a control group and the open-label design of the trial.
Limitations
The study had a small sample size and was not randomized, limiting the generalizability of the results.
Participant Demographics
{"total":50,"male":36,"female":14,"mean_age":59.1,"age_range":"27-80"}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website